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ABSTRACT 
Objective: The objective of the current study was to investigate the physician’s knowledge, attitude and practice towards pharmacovigilance. 
Methods: A mixed qualitative and quantitative method was conducted in this study using a face to face questionnaire among the physicians in the 
capital Sana'a, Yemen. 
Results: Of the 105 respondents (79 %) were male. Participants age mean was 35.55±4.45 y. Majority of physicians (73.3 %) had a moderate 
knowledge towards pharmacovigilance; (15.2 %) had a good knowledge and (11.4 %) had a poor knowledge. 35 (33.3 %) physicians were seen 
adverse drug reactions (ADRs) happened to their patients. Allergy was the most common ADRs. However, no ADR was reported. 66.7 % of 
physicians had a positive attitude towards pharmacovigilance. The most barriers reported by physicians were: lack of motivation and lack of 
knowledge about reporting system. Reported factors to encourage ADRs reporting were: attend courses or workshops; educational materials and 
simplification of reporting procedures.  
Conclusion: Majority of physicians in Sana’a, Yemen had moderate knowledge and postitive attitude towards pharmacovigilance. Educational and 
training programmes are the cornerstone of improving ADRs reporting in Yemen.  
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Pharmacovigilance science and activities are necessary for the safety and 
effcacy of medications [1]. Pharmacovigilance activities worldwide play 
very important role to ensure the rationality as well as safety of 
medicines and herbal medications which improve the cost-effectiveness 
[1-4]. One of the most important activities of pharmacovigilance is 
adverse drug reactions (ADRs) reporting [2].9 Pharmacovigilance 
defined by World Health Organization (WHO) decades ago as ‘‘the 
science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other possible 
drug-related problems’’ [1] ADRs defined by WHO as "any noxious, 
unintended, and undesired effect drug that occurs as a result of 
treatment with drug at a normal doses used in man for diagnosis, 
prophylaxis, and treatment" [5]. ADRs reported as an important cause of 
patient’s morbidity and mortality, admissions to the hospitals and 
increase the length of hospitalization as well as the cost of management 
[6-10]. Yemeni Pharmacovigilance Center (YPVC) was established on the 
capital Sana'a in early 2011 with the following aims and objectives; 
"early detection of adverse drug reactions (ADRs); detection of increase 
in frequency of (known) adverse reaction; identification of risk factors 
and possible mechanisms underlying adverse reactions; estimation of 
quantitative aspects of benefit/risk analysis and dissemination of 
information needed to improve drug prescribing and regulation; 
prevention of adverse drug reactions; drug quality surveillance; 
encouraging rational and safe use of drugs and communication with 
international institutions working in pharmacovigilance" [11, 12] The 
role of physicians is very important in reporting ADRs [13, 14]. 
Therefore, the aim of this study was to investigate the knowledge, 
attitude and barriers of Yemeni physicians towards pharmacovigilance, 
ADRs and ADRs reporting.  
MATERIALS AND METHODS  
Study design and study duration  
A cross-sectional study was conducted over a period of four months 
(1st August to 30th
Sample size 
 November 2016) among Physicians in Sana’a, Yemen.  
According to the annual reports of the Ministry of Public Health and 
Population 2014 the numbers of physicians are 1732 in the capital 
Sana'a [15]. Based on this statistics 315 physicians were selected 
conveniently from each region in the capital Sana'a to have an estimate 
of precision at the 95% confidence interval (CI), with an α = 0.05.  
Study tools 
A mixed qualitative and quantitative method was conducted in this 
study using a face to face questionnaire. The questionnaire was 
developed based on the information from the literature [16-18]. The 
questionnairewas pilot tested on a convenience sample of ten 
physicians in Ibb city to test the validity of the survey form. The final 
questionnaire was composed of six sections. Scoring system was used 
in this study to assess the knowledge and attitude of physcians in 
Yemen towards pharmacovigilance, ADRs and ADRs reporting. A score 
of 1 and 0 was given for each correct and wrong answer respectively, 
the answer was considered correct if the participant answered 
correctly or nearly to the correct answer. Total scores were calculated 
for each participant. A maximum 10 score were for evaluation the 
knowledge. A score equal to and greater than 6 was considered as 
good knowledge, scores 5 and 4 was considered as moderate 
knowledge, score less than 4 were considered as poor knowledge. 
Four levels Likert scaling (A: agree. SA: strongly agree. D: disagree 
and SD: strongly disagree.) 
Was used to explore the attitude, barriers and factors will encourage 
physicians in Yemen to report ADRs. A maximum 10 score were for 
evaluation the attitude. A score of 1 and 0 was given for each 
positive and negative answer respectively. Total scores were 
calculated for each participant. A score greater than or equal to 6 
was considered as positive attitude, score less than 6 were 
considered as negative attitude. Tow trained pharmacists were 
conducted this study by visiting physicians at their clinics or 
working hospitals.  
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This study was approved from University of Science and Technology, 
Yemen. Furthermore, written consent was also taken from the 
respondents. Questions that may related the personal information 
were avoided. 
Statistical analysis 
Data were entered and analysed using SPSS version 21 (SPSS 
Statistics for Windows, version 21.0, IBM Corp., USA). Differences in 
proportional were tested with Chi-square test or Fisher's exact test. 
Differences test in the means were test with the student t-test. All 
reported p-values are two tailed, and the result is significant if P-
value is ≤ 0.05. 
RESULTS 
A total of 400 physicians were interviewed. However only 105 
questionnaires were completed and analyzed. The mean age of the 
respondents was found to be 35.55±4.54 y. The characteristics of the 
study sample are presented in table 1. 
  
Table 1: Sociodemographic characteristics of the physicians 





83 (79 %) 





4 (3.8 %) 





26 (24.8 %) 






4 (3.8 %) 
83 (79 %)  
18 (17 %)  
Experience years  
less than 5 
5-10  
11-20  
More than 20  
 
10 (9.5 %) 
64 (61 %) 
25 (23.8 %) 
6 (5.7 %) 




26 (24.8 %) 
79 (75.2 %) 
 
Table 2: Knowledge related questions (correct answers) 
Statement Frequency (%)  
What is Pharmacovigilance? 94 (89.5 %) 
What is an Adverse Drug Reaction (ADR)? 95 (90 %) 
How does an ADR differ from a side effect? 89 (84.8 %) 
What are the types of ADRs? 11 (10.5 %) 
Why is pharmacovigilance important? 93 (88.6 %) 
Who should report ADRs? 17 (16.2%) 
How the report an adverse drug reaction can be done? 17 (16.2%) 
When the pharmacovigilance centre in Yemen was established? 3 (2.9 %) 
Where is the location of pharmacovigilance Centre in Yemen? 3 (2.9 %) 
What is the objectives of pharmacovigilance centre in Yemen? 1 (1%) 
Total scores: mean±(SD) 4.03±(1.60)  
Knowldge  
Good knowledge  
Moderate knowledge 
Poor knowledge  
 
16 (15.2 %) 
77 (73.3 %) 
12 (11.4%) 
 
Knowledge of physicians about pharmacovigilance, ADRs and 
ADRs reporting in Yemen 
The finding of this study showed that there were no significant 
association between the good knowledge and other factors (P-
value>0.05).  
Table 2 shows the knowledge of physicians towards 
pharmacovigilance, ADRs and ADRs reporting. 
Experience of yemeni physicians with adverse drug reactions 
(ADRs) and its reporting 
The finding of this study showed that there were 35 (33.3 %) 
physicians were detected and seen ADRs in their practice. The most 
common ADRs they detected were allergy. However they didn't 
report any ADR.  
Attitude of Yemeni physicians towards pharmacovigilance and 
adverse drug reactions (ADRs) reporting 
The finding of this study showed that there were no significant 
association between the positive attitude and other factors (P-
value>0.05).  
Table 3 shows the attitude of physicians towards 
pharmacovigilance, ADRs and ADRs reporting. 
Barriers of adverse drug reactions (ADRs) reporting 
Table 4 shows the barriers of ADRs reporting 
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Table 3: Attitude related questions (Positive attitude) 
Statement Frequency (%) 
I believe that pharmacovigilance is important 101 (96.2 %) 
Reporting ADRs is part of the professional role  86 (81.9 %) 
I want to be sure the ADR is related to the drug before reporting 63 (60 %) 
I report an ADR that causes:   
 a. hospitalisation 69 (65.7 %) 
 b. a life threatening situation 69 (65.7 %) 
 c. a congenital anomaly 69 (65.7 %) 
 d. persistent disability or incapacity 72 (68.6 %) 
 e. death of the patient 43 (41 %) 
I report to get more insight into ADR questions that I come across in my practice 8 (7.6 %) 
I report to show the patient that their concern is being taken seriously 45 (42.9 %) 
Total scores: mean±(SD) 5.95±(3.23) 
Positive attitude 70 (66.7 %) 
 
Table 4: Barriers of adverse drug reactions (ADRs) reporting 
Barrier Frequency (%) 
I don't report ADR because reporting form not available  15 (14.3 %) 
I don't report ADR because I don't know the address where these reports should be sent 16 (15.2 %) 
The reporting form too complicated  17 (16.2 %) 
Reporting ADRs is time consuming 14 (13.3 %) 
All serious ADRs are detected before registration  5 (4.8 %) 
I don't report ADR because I want to publish about them myself 2 (1.9 %) 
I don't report ADR because I am not convinced about the confidential handling of the reports 9 (8.6 %) 
I don't report ADR because I fear it may harm the confidence of my patients  20 (19 %) 
I don't report because I find it difficult to admit that the patients has been harmed  3 (2.9 %) 
I don't report because reporting may give the impression that I am ignorant concerning ADRs 3 (2.9 %) 
I don't report because I fear legal liability for the reported ADRs 4 (3.8 %)  
I am not motivated to report 105 (100 %) 
I don't report because I have insufficient clinical knowledge  4 (3.8 %) 
I don't report because I don't know how to report ADR 86 (66.7 %) 
I don't report because I am not convinced the ADR is caused by the drug 70 (38.1 %) 
 
Table 5: Factors encourage adverse drug reactions (ADRs) reporting 
Factors  Frequency (%) 
I will report if:  
 1. attend course or workshops to understand the reporting process 68 (64.2 %) 
 2. receive materials to understand the reporting process 77 (72.6 %) 
 3. More attention to ADR reporting in university curriculum  88 (83 %) 
 4. simplification of reporting procedure 69 (65.1 %) 
 5. promoting reporting as a part of professional duty  13 (12.3%) 
 6. there is a fee 89 (84 %) 
 7. I receive more feedback through mailings  39 (36.8 %) 
 8. compulsory reporting  43 (40.6 %) 
 
Factors encourage adverse drug reactions (ADRs) reporting 
Table 5 shows the factors encourage ADRs reporting. 
DISCUSSION  
This study aimed to explore the knowledge, attitude, practice and 
barriers of physicians toward pharmacovigilance, ADRs and ADR 
reporting in Yemen. This issue is very important to research in order to 
identify the required interventions to improve the ADRs reporting. The 
concept of pharmacovigilance in Yemen is new as the Yemeni 
Pharmacovigilance Center (YPVC) was established in early 2011 [11, 12]. 
Majority of physicians (73.3 %) had a moder knowledge towards 
pharmacovigilance, ADRs and ADRs reporting; (15.2 %) had a good 
knowledge and (11.4 %) had a poor knowledge. Majority of 
physicians couldn't have answered the questions related to ADRs 
reporting system and Yemeni pharmacovigilance system, while they 
answerd correctly questions related to the pharmacovigilance and 
ADRs. There is a difference between the findings of this study and 
the previous studies in terms of knowledge [19-23].  
This is could be due to that Yemeni Pharmacovigilance Center 
(YPVC) was established on the capital Sana'a in early 2011 and faced 
challenges in reporting and marketing its activities [11, 12, 24]. 
The finding of this study showed that there were 35 (33.3 %) 
physicians were detected and seen ADRs in their practice. The most 
common ADRs they detected were allergy. However they didn't 
report any ADR. There was a difference between this study and the 
previous studies [19-23] in terms of experience of reporting ADRs. 
This is could be due to that Yemeni Pharmacovigilance Center 
(YPVC) was established on the capital Sana'a in early 2011 and faced 
challenges in reporting and marketing its activities [11, 12, 24]. 
The finding of this study showed that (66.7 %) of physicians had a 
positive attitude towards pharmacovigilance and ADRs reporting. 
There was a similarity between the findings of this study and the 
previous studies [19-23]. 
The most barriers reported by physicians were: lack of motivation 
and lack of knowledge about reporting system. Several studies 
done previously reported that lack of sufficient knowledge 
among physicians about ADR reporting considered as a major 
factor for not reporting ADRs [19-23]. The finding of this study 
showed that the factors to encourage ADRs reporting were: 
attend course or workshops; educational materials and 
simplification of reporting procedure. ADRs could harm the 
patients and could be minimized by increasing the awareness of 
health care professionals about it [25].  
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The present study showed that the majority of physicians in Sana’a, 
Yemen had moderate knowledge about pharmacovigilance, ADRs 
and its reporting. They had a poor knowledge towards ADRs 
reporting. Physicians should take their responsibility towards 
pharmacovigilance. Education and training are the cornerstone of 
improving ADRs reporting in Yemen. The current study hasd several 
limitations: This study was conducted in the capital Sana'a only 
therefore; the findings cannot be generalized to other cities.  
RECOMMENDATIONS  
Future studies in other cities are highly recommended. Increase the 
awareness about pharmacovigilance and ADRs reporting among 
physicians as well as other health care professionals are highly 
recommended. Training and educational programmes are highly 
recommended to improve the ADRs reporting.  
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